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Abstract
Introduction: Bone and mineral metabolism is influenced by thyroid hormones, and levothyroxine (LT4) therapy may be associated with
reduced bone mass in postmenopausal women.
Material and methods: The aim of the study was to assess the influence of one year of LT4 treatment in a group of 21 adolescent girls with
euthyroid diffuse goiter. Lumbar (L2–L4) and total body bone mineral density (TOBMD) (Lunar — DXA), serum PTH, osteocalcin, bone
alkaline phosphate, vitamin D3, calcium, and phosphorus levels and urinary excretion of Ca, P, and hydroxyproline were measured before
and after one year of combined LT4 and iodine treatment.
Results: Patients were matched for age, sex, BMI, and maturation status, with controls treated with iodine only. Markers of bone turnover
changed in a similar manner in both groups. There was no significant difference in TOBMD value after one year of therapy between LT4
treated group and controls. Densitometric lumbar spine parameters increased significantly after 12 months in both groups, with no signi-
ficant differences between them.
Conclusion: It can be concluded that one year of LT4 treatment of adolescent girls with euthyroid diffuse goiter does not have a negative
impact on their bone remodelling and metabolism. (Pol J Endocrinol 2010; 61 (1): 14–19)
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Streszczenie
Wstęp: Metabolizm tkanki kostnej pozostaje pod wpływem hormonów tarczycy, a leczenie lewotyroksyną (LT4, levothyroxine) może być
związane z redukcją masy kostnej u kobiet po menopauzie. Celem pracy była ocena wpływu rocznej terapii łączonej lewotyroksyną
z preparatem jodu (grupa badana 21 dziewcząt z wolem rozlanym nietoksycznym), w porównaniu z grupą kontrolną leczoną tylko
preparatem jodu (22 dziewczęta z wolem nierozlanym nietoksycznym).
Materiał i metody: Gęstość mineralna tkanki kostnej całego ciała (TOBMD, total body bone mineral density) oraz w odcinku lędźwiowym
(L2–L4) została oceniona za pomocą badania densytometrycznego (DXA), w surowicy krwi oznaczono stężenia PTH, osteokalcyny, frakcji
kostnej fosfatazy alkalicznej, 25OHD3, wapnia i fosforanów, natomiast w dobowej zbiórce moczu oceniono wydalanie Ca, P i hydroxypro-
liny. Wszystkie parametry były ocenione na początku i po roku leczenia w obu grupach.
Wyniki: Nie wykazano różnic pomiędzy grupą badaną i grupą kontrolną w zakresie wieku oraz stopnia dojrzewania płciowego. Stężenia
markerów obrotu kostnego zmieniły się w podobny sposób w obu grupach. Gęstość mineralna tkanki kostnej całego ciała nie różniła się
znamiennie przed i po roku leczenie między grupą badaną i grupą kontrolną. Gęstość mineralna kości (BMD, bone mineral density)
w odcinku lędźwiowym wzrosła znamiennie w obu grupach po 12 miesiącach terapii, ale nie było znamiennej różnicy pomiędzy nimi.
Wniosek: Roczna terapia preparatem LT4 u dziewcząt z wolem rozlanym nietoksycznym nie wywiera negatywnego wpływu na remode-
ling i metabolizm tkanki kostnej. (Endokrynol Pol 2010; 61 (1): 14–19)
Słowa kluczowe: wole rozlane nietoksyczne, dzieci, lewotyroksyna, gęstość mineralna kości, markery obrotu kostnego
Introduction
Bones are a metabolically active tissue. Many hormo-
nes, most notably thyroid hormones, influence their
growth, maturity, and metabolism. They accelerate re-
modelling of bone tissue by inducing bone resorption
and formation [1]. Decreased growth and skeletal ab-
normalities in children with congenital hypothyroidism
are one of the spectacular examples of thyroid hormo-
ne importance in bone mineral metabolism. In patients
with hyperthyroidism, bone loss and increased levels
of bone specific markers may occur [2]. Several reports
have recognized that levothyroxine (LT4) therapy, par-
ticularly in suppressive doses, may be associated with
reduced bone mass and increased levels of bone meta-
bolism in adults, especially in postmenopausal women
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[3–5]. Some authors found similar results in subjects
receiving lower doses of LT4 [6, 7].
LT4 is commonly used in the therapy of children and
adolescents with euthyroid diffuse goiter. It is applied
with or without iodine supplementation, and in iodine
deficient areas therapy is usually started with iodine
only. There are scarce data on the bone metabolism
of children and adolescents receiving LT4 treatment
[8–12]. Puberty is the most important period for bone
acquisition. In this age, peak bone mass (PBM) deve-
lops and a potential LT4 negative influence may be as-
sociated with higher osteoporosis risk at a later age.
The aim of this study was to assess whether 12 mon-
ths of LT4 therapy in adolescent girls with euthyroid
diffuse goiter (EDG) might have a negative impact on
their bone mineral density and metabolism.
Material and methods
The study was performed on a group of 43 girls with
euthyroid diffuse goiter (EDG), who were included ac-
cording to the following criteria: no other diseases and
medications known to interfere with bone metabolism,
bone age ± 1 SD from chronological age, and puberty
stage 2 ≥ according to Tanner. Patients with osteopenia
and nodular goiter were also excluded. All girls inclu-
ded to the study had normocalcaemic diet (based on
3-day dietary diary). Informed consent was obtained from
each patient and her parents or guardians. The study
was approved by the institutional Ethics Committee.
In all subjects, ultrasonography (USG) of the thyro-
id gland and measurements of TSH and fT4 serum le-
vels were performed at study entry. All the girls were
randomly assigned to one of two groups.
The Study Group (SG) comprised 21 girls aged 10.3–
–17.3 years (mean 14.2 ± 1.8 SD). Their body mass in-
dex (BMI) was 15.8–22.2 kg/m2 (mean 19 ± 1.8 SD). The
girls were treated for 12 months with LT4 (Eltroxin
®
— GlaxoWellcome) in the initial dose 1.2–1.5 mg/kg b.w./
/day and iodine 100 mg/day (Jodid® — Merck). The the-
rapeutic LT4 dose was adjusted to keep TSH in normal-
low and fT4 in normal-high levels.
The Control Group (CG) comprised 22 girls aged
10.3–16.9 years (mean 14.6 ± 1.4 SD). Their body mass
index (BMI) was 14.9–24.8 kg/m2 (mean 19.9 ± 2.5 SD).
The girls were treated for 12 months with only iodine in
the dose of 100 mg/day. In this group, TSH and fT4 levels
remained within normal limits during the whole study.
There were no significant differences between SG
and CG with respect to age, stage of puberty, BMI, and
daily calcium consumption.
Every three months, a USG of the thyroid gland was
performed and TSH and fT4 serum levels were measu-
red in both groups. At study entry and after one year of
therapy, in both groups, serum was obtained for mar-
kers of bone formation (osteocalcin and bone specific
alkaline phosphatase), calcium, phosphorus, 25-hydro-
xyvitamin D, and intact parathyroid hormone. Samples
were frozen immediately and stored at –20°C until the
tests were run. A 24-hour urine sample was collected
from each individual for measurement of the markers
of bone resorption (hydroxyproline and calcium). Se-
rum calcium (Ca) levels, urinary excretion, and inorga-
nic phosphate (P) were measured using standard labo-
ratory methods. Serum parathyroid hormone levels
(PTH) were measured by immunoradiometric assay (Cis
bio international, France). Osteocalcin (OC) and bone
alkaline phosphatase (BALP) were measured in the se-
rum using two-site immunoradiometric assays (Inc Star
Corp. Stillwater, USA). Plasma 25-hydroxyvitamin D
(25OHD) levels were assessed by radioimmunocompe-
titive method. Colorimetric method was used for asses-
sment of urinary concentration of hydroxyproline (HP).
Bone mineral density of lumbar spine (L2–L4 BMD)
and total body (TOBMD) were measured at study entry
and after one year of treatment in both groups by dual
energy X-ray absorptiometry (DXA) with a Lunar DPXL
analyzer. The values were expressed as bone mineral
content (BMC [g]) and bone mineral density (BMD
[g/cm2]). For L2–L4, the BMD value was corrected by the
volume and expressed as volumetric bone mineral den-
sity (vBMD [g/cm3]) according to Kroger at al. [13].
The results were expressed as mean ± SD. The si-
gnificance of changes was analysed using Student’s
paired t-test (within-group comparisons) and unpaired
t-test (between group comparisons). In all statistical
analyses, p < 0.05 was considered significant.
Results
Markers of bone turnover
Serum TSH levels after 12 months of therapy decreased
significantly in the SG (p < 0.05). In the CG there was
no significant difference in TSH levels before and after
treatment with iodine. fT4 values increased significan-
tly in both groups (SG-p < 0.01; CG — p < 0.05). There
were no significant differences between the SG and CG
with respect to TSH and fT4 in all points of the study.
Serum Ca values did not differ significantly during the-
rapy and between the groups. Serum P values incre-
ased significantly after therapy (SG — p < 0.001; CG
— p < 0.01) without significant differences between the
groups. PTH levels increased significantly in both gro-
ups (p < 0.05) but remained within normal range du-
ring the whole study. They did not differ in children
from the study group in comparison to the controls.
A significant decrease in 25OHD3 value was observed
after one-year therapy in both the SG and CG groups
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(p < 0.05), but there were no significant differences be-
tween the SG and CG groups. Serum OC levels were
also significantly lower after one year in both groups
(SG — p < 0.01; CG — p < 0.05), without significant
differences between groups. BALP values were not si-
gnificantly different before and after treatment and be-
tween study groups. There was no significant differen-
ce with respect to urinary excretion of Ca, P, and HP at
the beginning or at the end of treatment. There was
also no difference between the groups at these two po-
ints of the study (Table I).
Densitometric parameters
The TOBMD value did not change significantly after
one year of therapy in any of the groups (Fig. 1). Densi-
tometric lumbar spine parameters increased significan-
tly after 12 months in both groups, without any signifi-
cant difference between SG and CG. BMC L2–L4 in SG
was 39.8 ± 10.83 g at baseline and 42.9 ± 9.18 g after
therapy (p < 0.01), and in CG 40.3 ± 9.84 g and 42.4 ±
± 8.54 g (p < 0.05), respectively (Fig. 2). BMD L2–L4 incre-
ased significantly in both groups after 12 months from
1.01 ± 0.2 g/cm2 to 1.06 ± 0.16 g/cm2 (p < 0.001) in SG
and from 1.05 ± 0.15 g/cm2 to 1.1 ± 0.13 g/cm2 (p < 0.01)
in CG (Fig. 3). Calculated vBMD L2–L4 values increased
insignificantly in the CG group and significantly in the
SG group (p < 0.01) after one year of treatment. vBMD
L2–L4 was not significantly different at the beginning
and the end of the study or between the groups (0.323 ±
± 0.055 g/cm3 and 0.336 ± 0.043 g/cm3 in SG versus 0.352 ±
± 0.046 g/cm3 and 0.355 ± 0.033 g/cm3 in CG) (Fig. 4).
Discussion
The accrual of bone mass during childhood and adole-
scence determines the peak bone mass, and a deficit in
bone mass gain may increase the risk of osteoporotic
fractures occurring at advanced age. It is well known
that women are more prone to osteoporosis. At the same
time, levothyroxine is more commonly prescribed for
girls as they suffer from enlarged thyroid more often
than boys do. The unfavourable effect of levothyroxine
therapy on bone mineralization may be associated with
excessive suppression of TSH, leading to subclinical
hyperthyroidism [14–16].
Table I. Bone metabolism parameters in both groups before and after one year of therapy (Mean ± SD)
Tabela I. Parametry metabolizmu tkanki kostnej w obu grupach, przed i po rocznej terapii (średnia ± SD)
SG p Value CG p Value
Before After 1 year Before After 1 year
Ca [mmol/L] 2.45±0.11 2.43±0.10 NS 2.46±0.10 2.45±0.07 NS
P [mmol/L] 1.66±0.23 1.33±0.32  < 0.001 1.65±0.19 1.35±0.25  < 0.01
PTH [pg/ml] 10.87±6.39 28.07±13.98  < 0.01 12.29±8.56 26.33±14.03  < 0.05
25OHD3 [ng/ml] 22.39±10.09 13.07±5.3  < 0.05 23.97±13.32 13.63±5.5  < 0.05
OC [ng/ml] 77.85±34.08 45.73±16.86  < 0.01 65.00±47.69 29.36±12.76  < 0.05
BALP [nmol/L/s] 642±337 626±534 NS 557±491 606±491 NS
HP [mmol/kg/day] 256.74±131.42 276.28±94.55 NS 237.43±89.32 252.11±131.8 NS
SG — study group; CG — control group; Ca — calcium; P — phosphorus; PTH – parathyroid hormone; 25OHD3 — 25-hydroxycholecalcipherol;
OC — osteocalcin; BALP — bone alkaline phosphatase; HP — hydroxyproline
Figure 1. Change in total bone mineral density (TOBMD) before
and after one year of treatment in the study group (SG) and in the
control group (CG). Values are mean ± SD
Rycina 1. Zmiany całkowitej gęstości mineralnej kości (TOBMD)
przed i po rocznym leczeniu w grupie badanej (SG) i grupie
kontrolnej (CG). Wartości wyrażono jako średnią ± SD
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Our prospective study was designed to examine
whether 12 months of treatment with levothyroxine has
a negative impact on bone mass metabolism and accru-
al in adolescent girls. The simplest method to assess bone
metabolism is determination of calcium concentration
in serum and its urine excretion. Since this parameter
has a low specificity it is usually assessed together with
other parameters of calcium-phosphate metabolism,
such as inorganic phosphates, parathyroid hormone,
and 25-hydroxycholecalciferol (25OHD3). Calcium con-
centrations in hyperthyroidism are usually normal or
slightly elevated. In the examined population of girls,
calcium concentrations in serum and in 24-hour urine
collection did not differ significantly after one-year the-
rapy compared to baseline. However, inorganic pho-
sphate concentrations decreased significantly both in
the group treated with LT4 and in the controls. No si-
gnificant change was found in urinary excretion of pho-
sphates in any of the groups. Serum PTH concentra-
tions increased significantly after one-year therapy in
both groups but remained within the normal range.
Such a change in PTH concentration mainly exerts an
anabolic effect on the bone tissue, activating synthesis
of an active form of D3 vitamin which leads to intensifi-
cation of bone mineralization and maintenance of nor-
mocalcaemia. It may also be responsible for a decrease
in inorganic phosphate concentration. Concentration
of hydroxyproline in urine is another marker of bone
resorption, as well as calcium urine excretion. Its renal
clearance is increased in hyperthyroidism and is nor-
Figure 2. Bone Mineral Content in lumbar spine (BMC L2-L4)
before and after one year of treatment in the study group (SG) and
in the control group (CG). Values are mean ± SD. * p < 0.01;
** p < 0.05 (v. before therapy)
Rycina 2. Zawartość minerału tkanki kostnej w odcinku
lędźwiowym kręgosłupa (BMC L2-L4) przed i po roku leczenia
w grupie badanej (SG) i grupie kontrolnej (CG). Wartości wyrażono
jako średnią ± SD. * p < 0.01; ** p < 0.05 (v. przed terapią)
Figure 3. Bone Mineral Density in lumbar spine (BMD L2-L4)
before and after one year of treatment in the study group (SG) and
in the control group (CG). Values are mean ± SD. * p < 0.001;
** p < 0.01 (v. before therapy)
Rycina 3. Gęstość mineralna tkanki kostnej w odcinku
lędźwiowym kręgosłupa (BMD L2-L4) przed i po roku leczenia
w grupie badanej (SG) i grupie kontrolnej (CG). Wartości wyrażono
jako średnią ± SD. * p < 0.001; ** p < 0.01 (v. przed terapią)
Figure 4. Volumetric Bone Mineral Density in lumbar spine
(vBMD L2-L4) before and after one year of treatment in the study
group (SG) and in the control group (CG). Values are mean ± SD.
* p < 0.01 (v. before)
Rycina 4. Objętościowa gęstość mineralna tkanki kostnej
w odcinku lędźwiowym kręgosłupa (vBMD L2-L4) przed i po roku
leczenia w grupie badanej (SG) i grupie kontrolnej (CG). Wartości
wyrażono jako średnią ± SD. * p < 0.01; (v. przed terapią)
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malised during therapy. In our study, concentrations
of HP in the excreted urine did not differ significantly
at the baseline and after one-year therapy in both gro-
ups. An explanation of the significant decrease of
25OHD3 concentrations in the group of girls treated
with LT4 and in the control group is difficult. One of
the possible mechanisms may be increased synthesis of
the active form of D3 vitamin.
The effect of LT4 therapy of non-toxic diffuse goitre
on bone formation markers was assessed mainly in post-
menopausal women, and the results were often diver-
gent [4, 7]. In this study, concentrations of osteocalcin
(OC) decreased significantly during one year of LT4 the-
rapy in both groups, which might be due to the fact
that osteocalcin concentrations decrease gradually until
the age of menarche, even by 1/3 of the value per year
[17, 18]. Bone alkaline phosphatase (BALP) did not dif-
fer significantly at the baseline and after one-year the-
rapy. These results are consistent with a similar study
performed on children with non-toxic diffuse goitre, in
which no significant changes of OC and BALP concen-
trations were found during one and a half years of the-
rapy with 100 mg/m2/day of LT4 [10]. Thus, although
other investigators found increased concentrations of
bone formation markers during levothyroxine therapy
in older patients [19–22], it seems that levothyroxine
therapy in peripubertal girls does not interfere with
physiological changes of bone formation markers.
Studies concerning the effect of LT4 therapy on bone
mineralization also refer mainly to postmenopausal
women, and most investigators showed significant
BMD decrease [4, 7, 23]. This was confirmed by meta-
analyses of data performed by Faber et al. [24] and Uz-
zan et al. [25]. Data published by Mohammadi showed
that in this age group the first 6 month of LT4 therapy
seem to be the most important [5]. Conversely, data
presented by Appetecchia in both pre- and postmeno-
pausal women with benign nodular goiter showed that
there were no adverse effects on BMD with an LT4 dose
which slightly suppressed TSH levels [26]. In the study
of Radetti at al. [8], adolescent girls receiving high do-
ses of LT4 for non-toxic goiter, Hashimoto«s thyroiditis,
or thyroid cancer for 6 to 96 months had a significant
reduction of bone mineral content as compared to the
controls. Tumer et al. [10] showed that treatment of non-
toxic diffuse goitre with lower LT4 does not does not
have a negative impact on bone remodelling and meta-
bolism. A similar observation was made by Poomtha-
vorn et al., who compared a group of young adults tre-
ated from early adolescence with suppressive doses of
LT4 (Hashimoto thyroiditis or euthyroid goiter) with
healthy controls and showed no detrimental effect on
peak bone mass attainment in the LT4-treated group
[12]. Recent data concerning long-term LT4 therapy in
children with congenital hypothyroidism showed no ne-
gative impact on BMD in young adulthood, even for pro-
longed treatment starting from the neonatal period [11].
The TOBMD, assessed in this study, did not differ
significantly after one-year therapy in any of the gro-
ups, and no statistically significant difference was
shown between the groups. The lack of significant
change of this parameter is associated with the fact
that during puberty certain regions of the skeleton
mainly increase their area whereas in others there is
intensified mineralization and an increase of BMC
expressed in grams.
Densitometric data indicate that LT4 treatment with
maintenance of TSH and fT4 concentrations within the
normal range did not influence bone mineral density
in our group of patients. The positive changes in BMC
and BMD in lumbar spine noted in both groups of girls
are due to the physiological process of bone mass ac-
crual in this age.
Conclusions
The results of the study show that correctly monitored
levothyroxine therapy in girls with non-toxic diffuse
goitre does not negatively influence their bone meta-
bolism and BMD accrual.
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